CYCC - Cyclacel Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue8431,9441,734
Cost of Revenue---
Gross Profit8431,9441,734
Operating Expenses
Research Development9,47712,38218,277
Selling General and Administrative5,5165,7325,894
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-14,150-16,170-22,437
Income from Continuing Operations
Total Other Income/Expenses Net376-316-212
Earnings Before Interest and Taxes-13,774-16,486-22,649
Interest Expense---
Income Before Tax-13,774-16,486-22,649
Income Tax Expense-1,983-2,144-3,243
Minority Interest---
Net Income From Continuing Ops-11,791-14,342-19,406
Non-recurring Events
Discontinued Operations--19
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-11,791-14,342-19,387
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-11,991-14,543-19,587